Article
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.
Oncogene - 31 Jan 2013
Wang Z, Yuan H, Roth M, Stark J M, Bhatia R, Chen W Y
Abstract excerpt
BCR-ABL transforms bone marrow progenitor cells and promotes genome instability, leading to development of chronic myelogenous leukemia (CML). The tyrosine kinase inhibitor imatinib effectively treats CML, but acquired resistance can develop because of BCR-ABL mutations. Mechanisms for acquisition of BCR-ABL mutations are not fully understood. Using a novel culture model of CML acquired resistance, we show that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.